STAT June 14, 2024
Elaine Chen

Good morning. We’ve made it to the end of the week! Let’s keep it short and get straight to the news of the day.

The need-to-know this morning

  • Cabaletta Bio presented early data on an experimental CD-19 targeting CAR-T therapy for autoimmune disease at a European rheumatology meeting.

Industry cheers Supreme Court decision on abortion pill

Biopharma leaders applauded the Supreme Court’s ruling yesterday that anti-abortion doctors did not have standing to challenge the FDA’s regulation of the abortion pill mifepristone.

The industry had warned that a decision favoring the plaintiffs could have destabilized the drug approval process. Last year, after a federal judge in Texas suspended the FDA’s approval of mifepristone, hundreds of biopharma executives and leaders...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others
Weight Loss Drugs’ Effects Could Be Improved by Priming Melanocortin System
J&J IRA pricing offer is in, as it sticks with 2025 guidance

Share This Article